Revolution Medicines, Inc. and Iambic Therapeutics announced on July 9, 2025, a multi-year technology and research collaboration to pursue novel drug candidates using Iambic’s AI models. This partnership aims to leverage Iambic’s leading AI-driven discovery platform to explore oncology targets that are challenging to address through conventional drug discovery methods.
Under the agreement, Iambic will train bespoke versions of its NeuralPLexer model using structures and molecular libraries provided by Revolution Medicines. Revolution Medicines will also gain access to Iambic’s PropANE model, a pre-trained graph neural network for lead selection and optimization across various drug properties.
Iambic will receive up to $25 million through upfront and expected near-term performance-based milestone payments, along with ongoing research and development reimbursements. Both companies will retain rights to a limited number of exclusive targets. This collaboration is expected to enhance Revolution Medicines' lead discovery and optimization processes, contributing to a more impactful and sustainable pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.